ENA Respiratory Begins Dosing in Phase 2 Study of INNA‑051 Nasal Spray
ENA Respiratory has initiated dosing in a Phase 2 clinical trial of its intranasal antiviral, INNA‑051. The study evaluates the spray’s ability to curb viral replication in the upper respiratory tract of adults presenting mild respiratory symptoms. Approximately 200 participants will receive the investigational product over a multi‑week period, with primary endpoints focused on viral load reduction and symptom duration. Positive results could position INNA‑051 as a non‑systemic, early‑intervention therapy for seasonal respiratory viruses.
True Colours
The article outlines the gold standard for spectroscopy in pharmaceutical labs, emphasizing that precise colour and turbidity measurements underpin brand integrity, product identification, and patient safety. It profiles six manufacturers—HunterLab, Shimadzu, PerkinElmer, Thermo Fisher Scientific, Agilent, and Mettler Toledo—detailing flagship...